14 September 2018
A new report by visiongain predicts that the global cholesterol-lowering drugs market will reach $24.63bn in 2019. This forecast and others appear in Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists, published in October 2015. Visiongain is a business information provider based in London, UK.
Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists report examines the current and future trends in the cholesterol-lowering drugs market. High cholesterol levels are present in a large percentage of the world’s population, leading to an increasing level of cardiovascular diseases. The important of managing cholesterol levels has become increasingly important to healthcare professionals in recent years, and the demand for more effective treatments has grown accordingly. A raft of new, more efficacious therapies is entering the market and these are forecast to lift revenues for the sector, with these medicines able to treat patients who have resisted current treatments.
In this report, we examine in detail a number of key national markets, as well as the sales of a wide range of leading cholesterol-lowering drugs in the following submarkets: statins and fixed-dose combinations, absorption inhibitors, ion-exchange resins fibrates, PCSK9 inhibitors and novel drugs. Forecasts are also provided for leading products in each submarket. Using our experience and market knowledge, as well as a wide variety of sources, forecasts have been built for both national markets and treatment areas, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.
Also included is analysis of the current leading players in the cholesterol-lowering drugs market. This includes a look at their current products, as well those presently in development. Recent financial performance is analysed, along with a breakdown of each company’s leading products and an analysis of news that may influence the course of the company.
Jack Evans, a pharmaceutical and medical devices industry analyst in visiongain, said: “The long-awaited market launch of PCSK9 inhibitors in 2015 could lead to a revolution in the treatment of patients with hypercholesterolaemia, even if these drugs are reserved for a select subgroup of patients.”
Visiongain’s report provides revenue forecasts to 2025 for the cholesterol-lowering drugs market and its leading national markets. The report discusses selected leading companies which hold significant shares of the market. These companies include AstraZeneca, Merck, Pfizer, Kowa, Daiichi Sankyo, Abbvie, Novartis, Sanofi and Amgen.
Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists
adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on email@example.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.
09 September 2020
The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.